Neurotech Pharmaceuticals Names Robert Dempsey to Board of Directors
Neurotech Pharmaceuticals, a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases, recently appointed Robert Dempsey to the organization’s Board of Directors.
Dempsey is currently serving as the Chief Executive Officer and President at AsclepiX Therapeutics. With over two decades of domestic and international experience leading successful drug development, business transactions, and commercialization in the ophthalmic space, he will bring deep relationships with Key Opinion Leaders and comprehensive knowledge of the ophthalmic ecosystem to Neurotech. He has held a variety of leadership roles across commercial, business development, medical affairs, and venture-backed startups.
Most recently, Dempsey served as the Chief Executive Officer for TearClear, successfully leading the company through Series B financing and positive FDA engagement. Prior to that, he served as the Global Head of Ophthalmology at Shire, then Takeda, responsible for one of the top 10 largest biopharma M&A deals in 2019.
Dempsey earned his MBA and BS from Northeastern University. View his full bio from Neurotech Pharmaceuticals here.
Executive Search Partnership: Neurotech Pharmaceuticals
ON Partners partner Suzanne Zebedee is proud to have partnered with Neurotech Pharmaceuticals on this successful board placement. Review more of our recent board and C-level executive search placements in our Life Sciences and Health Executive Talent Report.
Neurotech Pharmaceuticals, Inc. is a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables continuous delivery of protein drugs directly into the vitreous humor of the eye over an extended period. Neurotech is clinically studying its lead product candidate, NT-501, in a Phase 3 program to treat the orphan disease Macular Telangiectasia (MacTel) and in a Phase 2 study to treat Glaucoma. To learn more, visit www.neurotechusa.com.
To learn more about partnering with our executive search firm and board services team, meet our executive search consultants.
